Biogen Idec Total Revenues Increased 10% to $1.4 Billion in First Quarter 2013MarketWatch (press release)On April 4, 2013, Biogen Idec announced results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial were published in an on-line…
|
Drugmaker AbbVie rises following analyst upgrade
Yahoo! New Zealand News The company’s experimental products include the multiple sclerosis treatment daclizumab, multiple myeloma drug elotuzumab, veliparib for breast cancer, ABT-126 for Alzheimer’s disease and schizophrenia, and Elagolix, a treatment for endometriosis, … |
|
Drugmaker AbbVie rises following analyst upgrade
MSN Money The company’s experimental products include the multiple sclerosis treatment daclizumab, multiple myeloma drug elotuzumab, veliparib for breast cancer, ABT-126 for Alzheimer’s disease and schizophrenia, and Elagolix, a treatment for endometriosis, … |
Insider Monkey (blog)Biogen Idec Inc. (BIIB): What Goes up Must Come DownInsider Monkey (blog)On April 4, the company announced positive results from the phase 2 study of daclizumab HYP, another drug for MS which Biogen is developing in partnership wit…
Traders Recap: Biogen Idec, Array Biopharma, Universal Display, AmgenSBWire (press release)The company, on April 4, announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as an online article i…
|
MS: Schubhalbierung durch Daclizumab HYP?
DocCheck News “Innerhalb eines Jahres reduzierte Daclizumab HYP die Häufigkeit erneuter Erkrankungsepisoden bei Patienten mit einer schubförmig remittierenden Multiplen Sklerose um 54 Prozent”, berichtet Professor Ralf Gold, Direktor der Neurologischen Klinik am St. |
Bulls vs. Bears: Can Biogen Keep Booming?Investorplace.comLast week, BIIB announced positive phase 2 clinical trial results for its developmental MS drug daclizumab, noting that it significantly reduced brain lesions in patients with the relapsing-remi…
iStockAnalyst (press release)Abbvie, Inc: Pfizer Levoxyl Recall, Humira Provide Near-Term UpsideiStockAnalyst (press release)Most of these products are in economically attractive specialty markets (e.g. Elotuzumab in multiple myeloma, and Daclizumab in…
|
Surveyed U.S. Neurologists Would Prescribe Biogen Idec’s Tecfidera to 20 …
Sacramento Bee Clinical data and the opinions of thought leaders interviewed by Decision Resources indicate that other emerging agents—Lemtrada, ocrelizumab and AbbVie/Biogen Idec’s daclizumab—have advantages in reducing ARR over Teva’s Copaxone, the … |
 MarketWatch (press release) |
Surveyed US Neurologists Would Prescribe Biogen Idec’s Tecfidera to 20 …
MarketWatch (press release) Clinical data and the opinions of thought leaders interviewed by Decision Resources indicate that other emerging agents–Lemtrada, ocrelizumab and AbbVie/Biogen Idec’s daclizumab–have advantages in reducing ARR over Teva’s Copaxone, the … |